Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
William J. Gradishar, M.D., discusses the potential surgical implications for a woman with breast cancer who tests positive for a BRCA mutation, and why it is important to be aware of this genetic information.
In her talk, Hennessy will also emphasize the importance of educating patients about their cancers and care options, and of the need for physicians to consider treatments that go beyond the standard of care, including targeted medicines and clinical trials.
After a cancer diagnosis and treatment, one may question when they will actually start to feel “normal” again, whatever that may be. The Ovarian Cancer Prognosis and Lifestyle (OPAL) study set out to help women with ovarian cancer to understand just that.